^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    mitoxantrone

    i
    Other names: CL 232315, DHAQ, DHAD, NSC 279836, NSC 301739
    Company:
    Generic mfg.
    Drug class:
    Topoisomerase II inhibitor
    Related drugs:
    8d
    COMMODORE: A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation (clinicaltrials.gov)
    P3, N=276, Active, not recruiting, Astellas Pharma Inc | Trial completion date: Mar 2026 --> Mar 2027
    Trial completion date
    |
    FLT3 (Fms-related tyrosine kinase 3)
    |
    FLT3-ITD mutation • FLT3 mutation
    |
    cytarabine • Xospata (gilteritinib) • etoposide IV • mitoxantrone • fludarabine IV
    13d
    MyeChild 01: International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia (clinicaltrials.gov)
    P3, N=700, Recruiting, University of Birmingham | Active, not recruiting --> Recruiting
    Enrollment open
    |
    cytarabine • cyclophosphamide • Mylotarg (gemtuzumab ozogamicin) • mitoxantrone • fludarabine IV • busulfan
    19d
    XPO1 inhibitor selinexor suppresses homologous recombination by inhibiting E2F7 nuclear export in acute myeloid leukemia. (PubMed, Hematology)
    Drug interaction analyses assessed the combined effect of Selinexor and Mitoxantrone. E2F7-mediated HR inhibition is a key mechanism underlying Selinexor activity in AML. The XPO1-E2F7-HR axis represents a potential therapeutic vulnerability, supporting the rational combination of Selinexor with DNA-damaging agents to improve AML treatment outcomes.
    Journal • BRCA Biomarker • IO biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • RAD51 (RAD51 Homolog A) • XPO1 (Exportin 1) • E2F7 (E2F Transcription Factor 7)
    |
    Xpovio (selinexor) • mitoxantrone
    20d
    Application of Mitoxantrone Hydrochloride Injection as a Lymphatic Tracer in Dissection of Lymph Nodes Deep to the Right Recurrent Laryngeal Nerve During Gasless Trans-Subclavian Endoscopic Thyroidectomy for Thyroid Cancer (ChiCTR2600121631)
    P=N/A, N=300, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University; Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
    New trial
    |
    mitoxantrone
    20d
    The Application of New Lymphatic Tracers Mitozantrone Hydrochloride in Improving the Efficacy and Prognosis of Patients After Radical Surgery for Differentiated Thyroid Cancer (ChiCTR2600118271)
    P=N/A, N=90, Completed, Tianjin First Central Hospital; Tianjin First Central Hospital
    New trial
    |
    mitoxantrone
    24d
    MyeChild 01: International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia (clinicaltrials.gov)
    P3, N=700, Active, not recruiting, University of Birmingham | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    cytarabine • cyclophosphamide • Mylotarg (gemtuzumab ozogamicin) • mitoxantrone • fludarabine IV • busulfan
    26d
    RG1121403: Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms (clinicaltrials.gov)
    P1/2, N=62, Recruiting, University of Washington | Trial completion date: Dec 2027 --> Dec 2028 | Trial primary completion date: Dec 2026 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    Venclexta (venetoclax) • cytarabine • mitoxantrone • cladribine • Starasid (cytarabine ocfosfate)
    1m
    Identification of an Elusive CBFA2T3::GLIS2 Fusion Variant in Acute Megakaryoblastic Leukemia by Whole Genome Sequencing. (PubMed, EJHaem)
    The patient underwent induction chemotherapy with cytarabine and mitoxantrone, followed by salvage therapy with venetoclax and azacitidine, resulting in morphologic remission. Subsequent haploidentical hematopoietic stem cell transplantation achieved remission, with ongoing hematologic recovery. This case underscores the limitations of conventional molecular assays in detecting cryptic fusions and highlights the critical role of comprehensive genomic profiling in refining subclassification and optimizing therapeutic strategies in pediatric AML.
    Journal
    |
    CBFA2T3 (CBFA2/RUNX1 Partner Transcriptional Co-Repressor 3) • GLIS2 (GLIS Family Zinc Finger 2)
    |
    Venclexta (venetoclax) • cytarabine • azacitidine • mitoxantrone
    1m
    Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML (clinicaltrials.gov)
    P3, N=106, Completed, Arog Pharmaceuticals, Inc. | Recruiting --> Completed | N=322 --> 106 | Trial completion date: Oct 2024 --> Apr 2026 | Trial primary completion date: Oct 2024 --> Apr 2026
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    FLT3 (Fms-related tyrosine kinase 3)
    |
    FLT3-ITD mutation
    |
    cytarabine • crenolanib (ARO-002) • idarubicin hydrochloride • mitoxantrone
    2ms
    A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML (clinicaltrials.gov)
    P2, N=22, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: Sep 2029 --> May 2029 | Trial primary completion date: May 2027 --> Jan 2026
    Trial completion date • Trial primary completion date
    |
    FLT3 (Fms-related tyrosine kinase 3)
    |
    FLT3 mutation
    |
    cytarabine • etoposide IV • midostaurin • daunorubicin • idarubicin hydrochloride • mitoxantrone • fludarabine IV
    2ms
    RESOLVE trial: Registry and clinical trial comparing standard intensity and reduced intensity treatment in patients with AML or CLL who do not have residual disease. (2024-512503-39-00)
    P4, N=289, Recruiting, Medizinische Hochschule Hannover | N=128 --> 289
    Enrollment change • Minimal residual disease
    |
    Venclexta (venetoclax) • Imbruvica (ibrutinib) • cytarabine • Gazyva (obinutuzumab) • cyclophosphamide • etoposide IV • midostaurin • Vanflyta (quizartinib) • Mylotarg (gemtuzumab ozogamicin) • daunorubicin • idarubicin hydrochloride • mitoxantrone • cladribine • fludarabine IV • thiotepa • busulfan • Grafapex (treosulfan)
    2ms
    Integrating computational engines to identify TSPAN6 as a migrasome-associated target for immunotherapy sensitization. (PubMed, Front Immunol)
    Collectively, our findings establish TSPAN6 as a migrasome-related regulator driving adverse immunotherapy outcomes and responses. Targeting TSPAN6, potentially with mitoxantrone, presents a potential strategy to enhance immunotherapy efficacy.
    Journal • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TSPAN6 (Tetraspanin 6) • LGALS9 (Galectin 9) • NECTIN2 (Nectin Cell Adhesion Molecule 2)
    |
    mitoxantrone